Chimeric virus-like particles for the delivery of an inserted conserved influenza A-specific CTL epitope

Cheong, Wan Shoo; Reiseger, Jessica Jane; Turner, Stephen J.; Boyd, Richard; Netter, Hans Jürgen

doi:10.1016/j.antiviral.2008.10.003

Cited by 22 publications

(11 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The collected tissue culture supernatant was centrifuged using a benchtop centrifuge, then the supernatant was transferred into an ultracentrifuge tube, underlaid with a 20% sucrose cushion, and the particles pelleted by ultracentrifugation as described by Cheong et al (12). The supernatant was discarded, and the pelleted VLPs were resuspended in sodium-Tris-EDTA (STE) buffer (100 mM NaCl, 10 mM Tris [pH 8], 1 mM EDTA) for vaccination purposes.…”

Section: Methodsmentioning

confidence: 99%

“…The HBsAgS VLPs are processed by DCs and antigens presented via the major histocompatibility complex (MHC) class I and II antigen presentation pathways (10). In addition to HBsAgS VLPs being an immunogen of medical interest to prevent or to overcome HBV infections, the particles have been used as platforms for the delivery of foreign antigenic sequences and facilitated the induction of anti-foreign antigen-specific immune responses (11)(12)(13)(14)(15)(16)(17)(18). The most advanced malaria vaccine RTS,S is based on HBsAgS VLPs with a circumsporozoite epitope fused to the subunits.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Modification of Asparagine-Linked Glycan Density for the Design of Hepatitis B Virus Virus-Like Particles with Enhanced Immunogenicity

Hyakumura

Walsh

Thaysen‐Andersen

et al. 2015

J Virol

View full text Add to dashboard Cite

The small envelope proteins (HBsAgS) derived from hepatitis B virus (HBV) represent the antigenic components of the HBV vaccine and are platforms for the delivery of foreign antigenic sequences. To investigate structure-immunogenicity relationships for the design of improved immunization vectors, we have generated biochemically modified virus-like particles (VLPs) exhibiting glycoengineered HBsAgS. For the generation of hypoglycosylated VLPs, the wild-type (WT) HBsAgS N146 glycosylation site was converted to N146Q; for constructing hyperglycosylated VLPs, potential glycosylation sites were introduced in the HBsAgS external loop region at positions T116 and G130 in addition to the WT site. The introduced T116N and G130N sites were utilized as glycosylation anchors resulting in the formation of hyperglycosylated VLPs. Mass spectroscopic analyses showed that the hy-

show abstract

Section: Methodsmentioning

confidence: 99%

mentioning

confidence: 99%

Modification of Asparagine-Linked Glycan Density for the Design of Hepatitis B Virus Virus-Like Particles with Enhanced Immunogenicity

Hyakumura

Walsh

Thaysen‐Andersen

et al. 2015

J Virol

View full text Add to dashboard Cite

show abstract

“…Chimeric VLPs display heterologous antigens and can generate antipathogen and neutralizing antibodies such that immunization may also result in protection against pathogen challenge (99, 100). Many studies have been carried out with chimeric VLPs based on plant viruses (101–107), bacteriophages (108, 109), insect viruses (110), and animal polyomaviruses and papillomaviruses (97, 98).…”

Section: Immunization and Immunotherapy Using Virus-based Materialsmentioning

confidence: 99%

Virus-Based Nanoparticles as Versatile Nanomachines

et al. 2015

View full text Add to dashboard Cite

Nanoscale engineering is revolutionizing the way we prevent, detect, and treat diseases. Viruses have played a special role in these developments because they can function as prefabricated nanoscaffolds that have unique properties and are easily modified. The interiors of virus particles can encapsulate and protect sensitive compounds, while the exteriors can be altered to display large and small molecules in precisely defined arrays. These properties of viruses, along with their innate biocompatibility, have led to their development as actively targeted drug delivery systems that expand on and improve current pharmaceutical options. Viruses are naturally immunogenic, and antigens displayed on their surface have been used to create vaccines against pathogens and to break self-tolerance to initiate an immune response to dysfunctional proteins. Densely and specifically aligned imaging agents on viruses have allowed for high-resolution and noninvasive visualization tools to detect and treat diseases earlier than previously possible. These and future applications of viruses have created an exciting new field within the disciplines of both nanotechnology and medicine.

show abstract

“…In this context, virus-like particles (VLPs), such as particles composed of hepatitis B virus (HBV) surface protein HBsAg-S have been used as carriers to stimulate both humoral and cell-mediated responses (5,38,40,45,49,59). HBsAg-S is of particular interest in that not only can it be used as a carrier to stimulate an effective cell-mediated immunity (CMI) and humoral response for foreign epitopes, but the protein is also the most common molecule used in HBV vaccines, and consequently, recombinant derivatives have the potential to be exploited for dual-vaccination regimens.…”

Section: G Astric Colonization Bymentioning

confidence: 99%

Immunological Response to Parenteral Vaccination with Recombinant Hepatitis B Virus Surface Antigen Virus-Like Particles Expressing Helicobacter pylori KatA Epitopes in a Murine H. pylori Challenge Model

Kotiw

Johnson

Pandey

et al. 2012

Clin Vaccine Immunol

View full text Add to dashboard Cite

Virus-like particles (VLPs) based on the small envelope protein of hepatitis B virus (HBsAg-S) are immunogenic at the B-and T-cell level. In this study, we inserted overlapping sequences encoding the carboxy terminus of the Helicobacter pylori katA gene product into HBsAg-S. The HBsAg-S-KatA fusion proteins were able to assemble into secretion-competent VLPs (VLP-KatA). The VLP-KatA proteins were able to induce KatA-specific antibodies in immunized mice. The mean total IgG antibody titers 41 days post-primary immunization with VLP-KatA (2.3 ؋ 10 3 ) were significantly greater (P < 0.05) than those observed for vaccination with VLP alone (5.2 ؋ 10 2 ). Measurement of IgG isotypes revealed responses to both IgG1 and IgG2a (mean titers, 9.0 ؋ 10 4 and 2.6 ؋ 10 4 , respectively), with the IgG2a response to vaccination with VLP-KatA being significantly higher than that for mice immunized with KatA alone (P < 0.05). Following challenge of mice with H. pylori, a significantly reduced bacterial load in the gastric mucosa was observed (P < 0.05). This is the first report describing the use of VLPs as a delivery vehicle for H. pylori antigens.

show abstract

Chimeric virus-like particles for the delivery of an inserted conserved influenza A-specific CTL epitope

Cited by 22 publications

References 61 publications

Modification of Asparagine-Linked Glycan Density for the Design of Hepatitis B Virus Virus-Like Particles with Enhanced Immunogenicity

Modification of Asparagine-Linked Glycan Density for the Design of Hepatitis B Virus Virus-Like Particles with Enhanced Immunogenicity

Virus-Based Nanoparticles as Versatile Nanomachines

Immunological Response to Parenteral Vaccination with Recombinant Hepatitis B Virus Surface Antigen Virus-Like Particles Expressing Helicobacter pylori KatA Epitopes in a Murine H. pylori Challenge Model

Contact Info

Product

Resources

About